<p>N2OFF, Inc. (NASDAQ: NITO) has highlighted the work of its wholly-owned subsidiary, MitoCareX Bio Ltd., a specialty biotechnology company focused on developing small-molecule drugs that target human mitochondrial carriers. MitoCareX Bio utilizes proprietary approaches, including the MITOLINE™ algorithm, to model, screen, and validate compounds that target the SLC25A family of mitochondrial carriers. These efforts support the company’s precision pipeline addressing conditions such as cancer, metabolic diseases, and rare inherited disorders linked to mitochondrial dysfunction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646968-en) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

SBIO

NITO

NXTS

<p>N2OFF, Inc. (NASDAQ: NITO) has announced advancements by its subsidiary, MitoCareX Bio Ltd., in developing small-molecule drugs targeting human mitochondrial carriers. Utilizing the MITOLINE™ algorithm, MitoCareX Bio aims to address conditions like cancer and metabolic diseases linked to mitochondrial dysfunction. This initiative supports the company's precision pipeline for treating rare inherited disorders. The information is generated by Public Technologies and should not be considered financial or legal advice.</p>

MitoCareX Bio Advances Mitochondrial Drug Research Under N2OFF Inc